about
An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndromeLenalidomide: a brief review of its therapeutic potential in myelodysplastic syndromes.A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome.p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses.The role of haploinsufficiency of RPS14 and p53 activation in the molecular pathogenesis of the 5q- syndrome.Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies.Current therapeutic uses of lenalidomide in multiple myeloma.Important genes in the pathogenesis of 5q- syndrome and their connection with ribosomal stress and the innate immune system pathway.Evolving applications of lenalidomide in the management of anemia in myelodysplastic syndromes.Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes.Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis.Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer.SPARC silencing inhibits the growth of acute myeloid leukemia transformed from myelodysplastic syndrome via induction of cell cycle arrest and apoptosis.Haplo-insufficiency: a driving force in cancer.Molecular dissection of the 5q deletion in myelodysplastic syndrome.Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells.Haploinsufficiency of Apc leads to ineffective hematopoiesis.Myelodysplastic syndrome with chromosome 5 abnormalities: a nationwide survey in Japan.Dramatic response in the dependency to transfusion after low doses of lenalidomide treatment in a 5q-syndrome patient: a case report.
P2860
Q28472171-724DC1C9-89E6-43FE-9EDA-13C3602FE99CQ33379562-F614F661-28F5-4B1B-9537-2A77823E1EE0Q33579912-A2CF93A0-2F3B-4630-A69C-A1E8096F77A7Q33695954-C68710F2-6C4B-46D9-BA66-53D41D1AF072Q35230041-D4B00D16-AA4B-4A9F-AA9A-5D47EC6DD105Q35505803-F2FCF8B7-850A-4240-9D07-C20525CA1678Q35717799-E0027546-AF26-4F4C-AA14-957B92D0EB3DQ36376450-3D1DA8C1-8425-4A3E-B0E6-095A8EE63D29Q36417421-C934982A-E00C-4627-A382-0550D80B66D2Q36715246-E58E3A6F-9D4F-498F-8EB2-F11DB6B1D542Q36737106-D0414682-CD58-481E-93F0-4A3C51644FBFQ36832931-BAF105FD-1296-4D59-ABEA-A5B58B504EEFQ37423777-65E04B06-BA21-4D2C-B5B7-C3B7CDC7D15AQ37685420-617B029D-50BE-4C41-BE53-9551AEE61AB9Q37815124-4D9A902F-C840-4618-82F2-6AD3D0D82511Q37937810-BED70D2A-DDEF-44B1-845E-A535F947B169Q38507121-65F0FEAC-358A-4FD1-A13A-A61005F5B613Q42198272-6C315541-4ACA-4CF9-B5BF-DFDD95B9939CQ44125500-6C0FFED0-B092-450D-9DF3-CE27F27C3180Q54384826-7771FA9E-6EBC-46CD-AA93-D9B3565331EA
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
The 5q- syndrome.
@en
type
label
The 5q- syndrome.
@en
prefLabel
The 5q- syndrome.
@en
P2093
P2860
P1433
P1476
The 5q- syndrome.
@en
P2093
Giagounidis AA
Wainscoat JS
P2860
P304
P356
10.1080/10245330410001723824
P577
2004-08-01T00:00:00Z